EHR

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate...

Healthcare Staffing Market is expected to generate a revenue of USD 89.12 Billion by 2031, Globally, at 7.5% CAGR: Verified Market Research®

Verified Market Research® is pleased to announce the release of its latest market research report on the "Healthcare Staffing Market...

Andor Health and Ballad Health Partner to Empower Rural Appalachian Highland Communities with Revolutionary AI-Driven Virtual Care Platform

Robust Solution Increases Access to Care in Rural Communities with Limited Resources and Connectivity. ORLANDO, Fla., Sept. 17, 2024 /PRNewswire/...

Patient Engagement Tech Market to Grow by USD 37.4 Billion (2024-2028) with Chronic Disease Rise, AI’s Influence on Market Trends – Technavio Report

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape- The global patient engagement technology...

Health Systems Brace for Significant 2025 Cost Surge, Shift to GPOs and Outsourcing for Supply Chain Solutions, Black Book Survey Finds

Hospitals are not just outsourcing procurement but also forming deeper strategic partnerships with GPOs. These partnerships go beyond price negotiation...

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

US Digital Health Market Insights & Forecast 2024-2028, with Profiles of Leading Players Apple, McKesson, Alphabet, Cisco Systems, Cerner and Allscripts Healthcare Solutions – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "US Digital Health Market (by Technology & Component): Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's...

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract...

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a...

Treace Highlights New Product Innovations and Updated Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical...

error: Content is protected !!